{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:53:57Z","timestamp":1784105637478,"version":"3.55.0"},"reference-count":19,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to that of gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind research in these other forms of arthritis. We compared validated patient-reported outcome measures in patients with CPPD vs gout and OA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with CPPD were recruited from Brigham and Women\u2019s Hospital from 2018 to 2022. Presence of CPPD manifestations (acute calcium pyrophosphate [CPP] crystal arthritis, chronic CPP inflammatory arthritis, and\/or OA with CPPD) was confirmed by medical record review. Baseline surveys included the Gout Assessment Questionnaire version 2.0, modified to ask about \u201cpseudogout\u201d rather than \u201cgout\u201d; Routine Assessment of Patient Index Data 3 (RAPID-3); and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). We compared responses in patients with CPPD against published gout and OA cohort studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 47 patients with CPPD, the mean age was 71.9 years and 51% were female. Sixty-eight percent had at least 1 episode of acute CPP crystal arthritis, 40% had chronic CPP inflammatory arthritis, and 62% had OA with CPPD. Pain visual analog scale scores during a flare were similar in CPPD (mean 6.8 [SD 1.9]) and gout (mean 6.7 [SD 2.6];<jats:italic>P<\/jats:italic>= 0.78). Patients with CPPD reported significantly greater unmet treatment need than patients with gout (<jats:italic>P<\/jats:italic>= 0.04). RAPID-3 scores in CPPD (mean 8.1 [SD 5.6]) were lower than in gout (mean 12.1 [SD 6.2];<jats:italic>P<\/jats:italic>&lt; 0.01) and similar in OA (mean 6.8 [SD 6.1];<jats:italic>P<\/jats:italic>= 0.30). Patients with CPPD had significantly worse WOMAC stiffness scores than patients with mild OA, and significantly better WOMAC function scores than patients with severe OA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with CPPD may experience pain comparable to that in gout and OA and reported substantial unmet treatment needs.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2023-0031","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T08:07:26Z","timestamp":1682064446000},"page":"1058-1062","source":"Crossref","is-referenced-by-count":5,"title":["Patient-Reported Outcomes in Calcium Pyrophosphate Deposition Disease Compared to Gout and Osteoarthritis"],"prefix":"10.3899","volume":"50","author":[{"given":"Mary Grace","family":"Whelan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallie","family":"Altwies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"key":"2023122105350779000_50.8.1058.1","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1056\/NEJMra1511117","article-title":"Calcium pyrophosphate deposition disease","volume":"374","author":"Rosenthal","year":"2016","journal-title":"N Engl J Med"},{"key":"2023122105350779000_50.8.1058.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139105"},{"key":"2023122105350779000_50.8.1058.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780300811"},{"key":"2023122105350779000_50.8.1058.4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PROM.S8310","article-title":"Gout disease-specific quality of life and the association with gout characteristics","volume":"2010","author":"Hirsch","year":"2010","journal-title":"Patient Relat Outcome Meas"},{"key":"2023122105350779000_50.8.1058.5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/acr.22674","article-title":"Longitudinal course of physical function in people with symptomatic knee osteoarthritis: data from the Multicenter Osteoarthritis Study and the Osteoarthritis Initiative","volume":"68","author":"\u00d8iestad","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2023122105350779000_50.8.1058.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080506"},{"key":"2023122105350779000_50.8.1058.7","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"key":"2023122105350779000_50.8.1058.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.008"},{"key":"2023122105350779000_50.8.1058.9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/acr.21793","article-title":"Patient self-report RADAI (Rheumatoid Arthritis Disease Activity Index) joint counts on an MDHAQ (Multidimensional Health Assessment Questionnaire) in usual care of consecutive patients with rheumatic diseases other than rheumatoid arthritis","volume":"65","author":"Castrej\u00f3n","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2023122105350779000_50.8.1058.10","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/kez431","article-title":"A prospective study of dual-energy CT scanning, US and X-ray in acute calcium pyrophosphate crystal arthritis","volume":"59","author":"Tedeschi","year":"2020","journal-title":"Rheumatology"},{"key":"2023122105350779000_50.8.1058.11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/acr.24132","article-title":"Classifying pseudogout using machine learning approaches with electronic health record data","volume":"73","author":"Tedeschi","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2023122105350779000_50.8.1058.12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11136-018-1978-1","article-title":"Problems persist in reporting of methods and results for the WOMAC measure in hip and knee osteoarthritis trials","volume":"28","author":"Copsey","year":"2019","journal-title":"Qual Life Res"},{"key":"2023122105350779000_50.8.1058.13","first-page":"2433","article-title":"Impact of osteoarthritis on quality of life in a Hong Kong Chinese population","volume":"31","author":"Woo","year":"2004","journal-title":"J Rheumatol"},{"key":"2023122105350779000_50.8.1058.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350502"},{"key":"2023122105350779000_50.8.1058.15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s13075-014-0458-4","article-title":"Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial","volume":"16","author":"Finckh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2023122105350779000_50.8.1058.16","first-page":"327","article-title":"Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD","volume":"23","author":"Rothschild","year":"1997","journal-title":"Compr Ther"},{"key":"2023122105350779000_50.8.1058.17","unstructured":"Pascart T , Robinet P , Ottaviani S , Colchicine or prednisone for the treatment of acute calcium pyrophosphate deposition arthritis: a multicenter randomized controlled trial [abstract]. Arthritis Rheumatol 2022;74 Suppl 9."},{"key":"2023122105350779000_50.8.1058.18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.semarthrit.2020.09.021","article-title":"Outcome domains reported by patients, caregivers, healthcare professionals and stakeholders for calcium pyrophosphate deposition (CPPD): a content analysis based on semi-structured qualitative interviews from the OMERACT CPPD working group","volume":"51","author":"Fuller","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2023122105350779000_50.8.1058.19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/art.40381","article-title":"Brief report: validation of a definition of flare in patients with established gout","volume":"70","author":"Gaffo","year":"2018","journal-title":"Arthritis Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-0031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T13:35:34Z","timestamp":1703165734000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-0031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.3899\/jrheum.2023-0031"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-0031","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]}}}